Interplay between humoral and CLA+ T cell response against Candida albicans in psoriasis by de Jesús-Gil, Carmen et al.
 International Journal of 
Molecular Sciences
Article
Interplay between Humoral and CLA+ T Cell Response against
Candida albicans in Psoriasis
Carmen de Jesús-Gil 1 , Lídia Sans-de San Nicolàs 1, Ester Ruiz-Romeu 1, Marta Ferran 2, Laura Soria-Martínez 1,
Irene García-Jiménez 1, Anca Chiriac 3, Josep Manel Casanova-Seuma 4, Josep Manel Fernández-Armenteros 4,




Citation: de Jesús-Gil, C.; Sans-de
San Nicolàs, L.; Ruiz-Romeu, E.;
Ferran, M.; Soria-Martínez, L.;
García-Jiménez, I.; Chiriac, A.;
Casanova-Seuma, J.M.;
Fernández-Armenteros, J.M.; Owens,
S.; et al. Interplay between Humoral
and CLA+ T Cell Response against
Candida albicans in Psoriasis. Int. J.
Mol. Sci. 2021, 22, 1519. https://
doi.org/10.3390/ijms22041519
Academic Editor: Joanna Narbutt
Received: 21 January 2021
Accepted: 29 January 2021
Published: 3 February 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Translational Immunology, Department of Cellular Biology, Physiology and Immunology, Faculty of Biology,
Universitat de Barcelona, 08028 Barcelona, Spain; cdejesus@ub.edu (C.d.J.-G.);
li.sns25@gmail.com (L.S.-d.S.N.); eruizromeu@gmail.com (E.R.-R.); laurasoriamartinez@gmail.com (L.S.-M.);
irenegarciajimenez@ub.edu (I.G.-J.)
2 Department of Dermatology, Hospital del Mar, 08003 Barcelona, Spain; mferran@parcdesalutmar.cat (M.F.);
rpujol@parcdesalutmar.cat (R.M.P.)
3 Department of Dermatophysiology, Apollonia University, 700613 Iasi, Romania; ancachiriac@yahoo.com
4 Department of Dermatology, Hospital Universitari Arnau de Vilanova, 25198 Lleida, Spain;
josepmanel.casanova@udl.cat (J.M.C.-S.); josepmanelfa27@gmail.com (J.M.F.-A.)
5 Translational Sciences, Incyte Corporation, Wilmington, DE 19803, USA; SOwens@incyte.com (S.O.);
mhowell@dermtech.com (M.D.H.)
6 Macrophage Biology, Department of Cellular Biology, Physiology and Immunology, Faculty of Biology,
Universitat de Barcelona, 08028 Barcelona, Spain; acelada@ub.edu
* Correspondence: luis.santamaria@ub.edu; Tel.: +34-677375160
Abstract: Candida albicans (CA) infections have been associated with psoriasis onset or disease flares.
However, the integrated immune response against this fungus is still poorly characterized in psoriasis.
We studied specific immunoglobulins in plasma and the CA response in cocultures of circulating
memory CD45RA− cutaneous lymphocyte antigen (CLA)+/− T cell with autologous epidermal cells
from plaque and guttate psoriasis patients (cohort 1, n = 52), and also healthy individuals (n = 17).
A complete proteomic profile was also evaluated in plaque psoriasis patients (cohort 2, n = 114)
regarding their anti-CA IgA levels. Increased anti-CA IgA and IgG levels are present in the plasma
from plaque but not guttate psoriasis compared to healthy controls. CA cellular response is confined
to CLA+ T cells and is primarily Th17. The levels of anti-CA IgA are directly associated with CLA+
Th17 response in plaque psoriasis. Proteomic analysis revealed distinct profiles in psoriasis patients
with high anti-CA IgA. C-C motif chemokine ligand 18, chitinase-3-like protein 1 and azurocidin
were significantly elevated in the plasma from plaque psoriasis patients with high anti-CA levels and
severe disease. Our results indicate a mechanism by which Candida albicans exposure can trigger a
clinically relevant IL-17 response in psoriasis. Assessing anti-CA IgA levels may be useful in order to
evaluate chronic psoriasis patients.
Keywords: psoriasis; Candida albicans; IgA; CLA; IL-17
1. Introduction
Psoriasis is a T cell-mediated skin disease resulting from epithelial and immunological
cells’ interactions [1]. Psoriasis onset is influenced by genetic and environmental factors,
particularly infections. Psoriasis flares have been attributed to Candida albicans infections [2].
Several studies have confirmed increased Candida albicans colonization of the oral [3–7]
and gut [3,7] mucosa in psoriasis patients compared to healthy individuals. Whereas
some authors revealed an association between C. albicans existence at mucosal sites and
psoriasis severity [3,5,7], others did not find a correlation [4,8,9]. Likewise, the presence
of Candida albicans at cutaneous levels is still controversial. Most skin mycobiome studies
Int. J. Mol. Sci. 2021, 22, 1519. https://doi.org/10.3390/ijms22041519 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2021, 22, 1519 2 of 13
have not revealed differences between psoriasis and healthy individuals’ Candida spp.
levels [4,10–16]. However, Sarvtin T. and colleges found elevated C. albicans in lesional
skin from the trunk compared to either adjacent normal skin or healthy controls’ skin [6].
Furthermore, Salem I. et al. recently reported the presence of higher C. albicans in non-
lesional skin swabs [17].
Currently, the evidence of microbes’ presence in psoriatic patients is focused on
complex DNA-based technologies [18]. Specific immunoglobulins assess environmental
microorganism exposure. The isotypes observed in immunoglobulins can elucidate the
mechanisms of antigen encounters [19]. Initial studies of anti-Candida antibody levels did
not observe differences between patients with psoriasis and healthy individuals [10,20].
Recently, however, Liang YS et al. showed increased anti-whole cell antigen IgG and
decreased anti-soluble antigen IgA and IgM in serum from psoriasis patients versus healthy
individuals [21]. However, Sarvtin MT et al. reported decreased anti-Candida IgM, IgA and
IgG levels in psoriasis patients compared to controls [6]. As such, the humoral response
against Candida albicans in psoriasis patients remains controversial.
The IL-23/IL-17/IL-22 axis protects us against Candida albicans [22], but it also plays
a key role in psoriasis development. The study of Candida albicans in psoriasis patients
is very limited and mainly studied in total peripheral blood mononuclear cells [23–25].
Schlapbach et al. reported IL-9 induction by C. albicans specifically on skin-tropic T helper
cells from healthy donors, along with increased IL-9+ cells in psoriasis lesions [26]. Likewise,
previous data from our group described the increased induction of IL-9, IL-17A and IFN-
γ by CLA+CD4+ T cells after C. albicans activation in four psoriasis patients compared
to healthy individuals [27]. Investigating CD45RA−CLA+ memory T cell-induced IL-
17 responses to a microorganism with microbe-specific immunoglobulins levels with
clinical features can help to understand how microorganisms might modulate psoriasis
pathogenesis from a more holistic view. We have recently demonstrated the relevance of
this approach for Streptococcus pyogenes, showing that bacteria specific-IgA and CLA+ T
cell IL-17 response are associated in psoriasis patients [28].
In this study, we investigated humoral and cellular immune responses against
Candida albicans in psoriasis patients, comparing plaque and guttate forms. The asso-
ciation between antibodies and cytokine responses was also assessed. Finally, we examined
the proteomic profile in plasma from plaque psoriasis patients. Altogether, our data illus-
trate the heterogeneity of Candida albicans exposure in psoriasis, which might reflect the
pathological mechanisms.
2. Results
2.1. Description of Patients and Controls Samples Used in Different Experiments
A total of 166 psoriasis patients and 17 healthy individuals were enrolled. Psoriasis
patients were classified in cohort 1 (n = 52), consisting of both plaque and guttate forms of
the disease, and cohort 2 (n = 114), which included only plaque psoriasis patients. Complete
humoral and cellular responses against Candida albicans were assessed in cohort 1, as well
as ELISAs to validate differentially expressed proteins. Cohort 2 was only studied for
C. albicans-specific IgA levels and the complete proteomic profiling in plasma. Detailed
information of the source and experiments performed with each cohort can be found in
Supplementary Table S1. The inclusion and exclusion criteria for each cohort are detailed
in Section 4.
2.2. Plaque Psoriasis Patients Have Increased Levels Candida Albicans-Specific IgA and IgG
Plasma samples from psoriasis cohort 1 (n = 52) and healthy (n = 17) individuals were
analyzed. The clinical features of plaque and guttate psoriasis patients from cohort 1 are
summarized in Table 1. The specific IgA and IgG for Candida albicans in plasma samples
were tested by ELISA (referred as anti-CA IgA or IgG). The levels of anti-CA IgA and IgG
were significantly increased in the plasma from plaque psoriasis patients compared to
guttate psoriasis and healthy controls, which presented similar anti-CA IgA and IgG levels
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(Figure 1a,d). IgA and IgG subtypes were also assessed. Both anti-CA IgA1 and IgA2 were
significantly increased in plaque psoriasis patients in comparison to guttate psoriasis and
healthy individuals (Figure 2b,c), whereas no differences were observed between guttate
psoriasis and controls. Interestingly, anti-CA IgA and IgA2 levels positively correlated
with disease duration only in plaque psoriasis (IgA Spearman r: 0.4435, p value = 0.03;
IgA2 r = 0.4082, p value = 0.0477, data not shown). Anti-CA IgG1, IgG2 and IgG3 were
detected in both psoriatic groups and healthy individuals (Figure 1e–g), whereas anti-
CA IgG4 was not detectable (Figure 1h). Nonetheless, only anti-CA IgG3 levels were
significantly increased in plaque psoriasis compared to controls (Figure 1g). Additionally,
we used a commercial diagnostic kit for the quantitative determination of IgA antibodies
against C. albicans in human plasma, revealing current infection. Both psoriasis and healthy
individuals presented negative antibody titer (< 8 U/mL), indicating no fresh C. albicans
infection (Figure S1). Interestingly, plaque psoriasis patients showed significantly higher
anti-CA titer compared to healthy controls, supporting our results.
Figure 1. Plaque, but not guttate, psoriasis patients present increased IgA-1, IgA-2 and IgG-3 against Candida albicans
compared to healthy controls. Specific immunoglobulins recognizing C. albicans cellular antigens (CA) were detected
through ELISA in plasma collected from the blood of plaque psoriasis (n = 31, •), guttate psoriasis (n = 21, •) and healthy
controls (n = 17, #). Net OD of 1/100 diluted plasma is reported. Plasma levels of IgA (a), IgA-1 (b), IgA-2 (c), IgG (d), IgG1
(e), IgG2 (f), IgG3 (g) and IgG4 (h) against CA are shown. Statistics lines are represented as mean with 95% confidence
interval. Dotted lines indicate the mean background signal. A Mann–Whitney test was used to compare between groups,
and p values are indicated as: ns: p > 0.05; *: p < 0.05; **: p < 0.01.
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Table 1. Clinical features of psoriasis patients in cohort 1 according to the subtype of disease.
Plaque Guttate p Value
Number of patients 31 21 NA
Age (mean ± SD) 46.65 (11.97) 32.65 (10.92) ***
PASI (mean ± SD) 13.74 (5.99) 7.23 (2.91) ***
HLA-Cw*6
% (n)
Positive 32.26 (10) 85.71 (18) NA
Negative 61.29 (19) 14.29 (3) NA
UK 6.45 (2) - NA
Mann–Whitney test was used to compare quantitative variables, p values are indicated as ns: p > 0.05;
***: p < 0.001. NA = not assigned. Bold: the clinical features.
Figure 2. Th17 and Th9 responses to C. albicans are confined to CLA+ T cells. IL-17F (a), IL-17A (b), IL-9 (c) and IFN-γ (d)
levels were measured in culture supernatants from CLA+ or CLA− T cells cocultured with autologous epidermal cells (EPI)
after 5 days, in basal conditions (M) and stimulated with C. albicans (CA), in plaque psoriasis (n = 31), guttate psoriasis
(n = 21) and healthy controls (n = 12). Column bars are represented as mean with 95% confidence interval. Wilcoxon test
was used to compare two conditions within psoriasis or controls (double-pointed line), whilst Mann–Whitney test was
used to compare psoriasis versus controls (single-pointed line). For both, p values are indicated as ns: p > 0.05; *: p < 0.05;
**: p < 0.01; ***: p < 0.001; ****: p < 0.0001.
2.3. Candida Albicans-Induced Th17 and Th9 Responses Are Confined to CLA+ T-cells and
Dominated by IL-17F
C. albicans cellular response was assessed in psoriasis cohort 1 (n = 52) and healthy
controls (n = 17). Cocultures of CD45RA− memory CLA+ or CLA− T cells with autologous
epidermal cells were left untreated or activated with C. albicans extract. After 5 days of
culture, cytokines were quantified in stimulated supernatants. Plaque and guttate psoriasis
patients showed significant CLA+ T cells-dependent CA-mediated induction of IL-17F,
IL17A, and IL-9 compared to unstimulated CLA+T/EPI and CA-stimulated CLA−T/EPI
cocultures (Figure 2a–c). Notably, CA-induced IL-17F and IL-17A levels in CLA+T cells
were significantly higher in cocultures from guttate psoriasis compared to those of plaque
psoriasis. CA induction of IFN-γ was also higher in guttate psoriasis, whereas IL-9 induc-
tion was slightly increased in plaque psoriasis, but not significantly differently. Cytokine
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responses were also detected in healthy controls’ CLA+T/EPI cocultures after CA activa-
tion. Only IL-17F and IL-17A responses were significantly associated with CLA+ T cells
when compared to CA-stimulated CLA−T/EPI coculture in healthy subjects; however, no
substantial differences were found when compared to the CLA+T/EPI untreated condi-
tion. Interestingly, levels of CA-induced IL-9 by CLA+T/EPI cocultures were significantly
higher in psoriasis than in healthy individuals (Figure 2d). Additionally, single cultures of
epidermal cells as well as CLA+ and CLA− T cells were left untreated and stimulated with
CA for 5 days. IL-17A and IFN-γ induction was measured in culture supernatants. The
IL-17A response was almost null even in CA-stimulated conditions (Figure S2a). Similarly,
although low IFN-γ levels were detected in CA-stimulated conditions, still this response
was similar to the one found in untreated cultures (Figure S2b). Therefore, only when CLA+
T cells are cultured in the presence of autologous epidermal cells is increased cytokine
response to C. albicans stimulation observed.
2.4. Candida Albicans’ Specific IgA Plasma Levels and IL-17 T cell Responses Are Directly
Associated in Plaque Psoriasis Patients
Correlations between anti-CA IgA or IgG and the different measured cytokines were
assessed in psoriasis cohort 1 (n = 52) and healthy controls (n = 17). Only for plaque
psoriasis patients were levels of anti-CA IgA positively associated with IL-17F and IL-17A
responses (Table 2), in CLA+ T cells/EPI but also in CLA− T cells/EPI cocultures. This
association was not observed for guttate psoriasis (data not shown) or healthy controls, or
for specific IgG (Table 2). Additionally, disease duration was significantly correlated with
CA-induced CLA+ T cell dependent IL-17F and IL-17A, and CLA− T cell dependent IL-17F
production in plaque psoriasis (CLA+ T-IL-17F: r = 0.5569, p = 0.0047; CLA− T-IL-17F:
r = 0.4112, p = 0.0459 and CLA+ T-IL-17A: r = 0.5873, p = 0.0026).
Table 2. Correlation of anti-CA IgA or IgG and cytokine responses to Candida albicans in CLA+ or CLA− T cells cocultured
with autologous epidermal cells. Spearman ρ and p values are indicated (ns: p > 0.05; *: p < 0.05; **: p < 0.01).
Anti-CA IgA Anti-CA IgG
Coculture




IL-17F 0.3735 0.0385 * −0.0842 0.6525 ns
IL-17A 0.4798 0.0063 ** 0.0349 0.8521 ns
IL-9 0.2363 0.2006 ns 0.1250 0.5028 ns
IFN-γ 0.1872 0.3219 ns 0.0116 0.9515 ns
CLA−T/EPI
IL-17F 0.5028 0.0039 ** −0.0267 0.8864 ns
IL-17A 0.4714 0.0074 ** 0.0625 0.7383 ns
IL-9 0.2558 0.1724 ns 0.1183 0.5264 ns




IL-17F −0.4496 0.1681 ns 0.0458 0.9015 ns
IL-17A −0.4307 0.1622 ns −0.0392 0.9061 ns
IL-9 −0.5691 0.0591 ns 0.0734 0.8288 ns
IFN-γ −0.2203 0.5015 ns −0.3885 0.2227 ns
CLA−T/EPI
IL-17F 0.2197 0.5192 ns 0.2197 0.5192 ns
IL-17A −0.1706 0.5948 ns 0.2538 0.4246 ns
IL-9 −0.2527 0.4394 ns 0.0161 0.9697 ns
IFN-γ −0.0275 0.9394 ns 0.4773 0.1258 ns
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2.5. Proteomic Profile of Plasma from Psoriasis Patients according to Anti-CA IgA Levels
Specific IgA was assessed in plasma samples from psoriasis cohort 2 (n = 114). Based on
the upper limit of the 95% confidence interval and the maximum optical density (OD) signal
of anti-CA IgA from healthy individuals, patients were stratified in the following groups: low
(OD < 1.5), intermediate (OD = 1.5–3) and high (OD > 3). Broad proteomic expressions of 1012
proteins were compared between groups using a generalized linear model. Table S2 shows the
differentially expressed proteins between low and high groups ordered by fold change.
Positive fold change values represent higher protein levels in the high IgA-Candida group.
A total of 27 proteins differed significantly between the high and low groups using a raw
p value. Of these, two proteins yielded >30% of values below the limit of detection and
should be interpreted with caution. Although no significant differences remained after
false discovery rate (FDR) p value correction, some proteins of potential interest were
identified and selected for further validation in samples from cohort 1 (n = 52) and healthy
individuals (n = 17). Four proteins were found with increased presence in plasmas with high
anti-CA IgA (eosinophil cationic protein (RNASE3/ECP), chitinase-3-like protein 1 (CHI3L1),
azurocidin (AZU1) and C-C motif chemokine 18 (CCL18)), and two that were found to be
decreased (Follistatin (FST) and Fas-ligand (FSLG)). Plasma levels of CCL18, CHI3L1 and AZU1
were significantly increased in plaque compared to guttate psoriasis (Figure 3a–d). CHI3L1
levels were significantly higher in plaque but not guttate psoriasis when compared to controls
(Figure 3b). Similar results were obtained for CCL18, although differences between plaque
psoriasis and healthy individuals did not reach statistical significance (Figure 3a). Conversely,
AZU1 and RNASE/ECP protein levels were significantly higher in both plaque and guttate
psoriasis compared to healthy subjects (Figure 3c,d). Plaque psoriasis patients showed significant
positive correlation between CCL18 levels and PASI, as well as between CHI3L1 levels and age
of onset (Figure 3e,f), whereas a strong negative correlation was found for CHI3L1 and disease
duration (Figure 3g). In psoriasis patients, we also found significant direct correlations between
levels of CCL18, CHI3L1 or AZU1 and PASI, as well as age of onset (Figure S3). No differences
were observed for FST and FSLG (data not shown).
Figure 3. AZU1, CCL18, CHI3L1 and AZU1 are significantly increased in plasma from plaque psoriasis compared to guttate
or/and healthy controls. CCL18, CHI3L1, AZU1 and RNASE3/ECP levels were assessed by ELISA in plasmas from plaque
psoriasis (n = 31, •), guttate psoriasis (n = 21, •) and healthy individuals (n = 16, #). (a–d) Comparison of levels detected between
plaque and guttate psoriasis versus controls. In plaque psoriasis patients, relevant correlations between (e) CCL18 and disease
severity (PASI), as well as CHI3L1 and age of onset (f) or disease duration (g), were found. A Wilcoxon test was used to compare
two conditions within psoriasis or controls. Spearman test was used for correlations. Spearman coefficient (r) and p values (p) are
indicated as ns: p > 0.05; *: p < 0.05; **: p < 0.01; ****: p < 0.0001.
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3. Discussion
Microorganisms can affect psoriasis presentation and patient’s natural history [2,29].
While lymphoid B-cells are dispensable for psoriasis development, B-cell dysregulation and
increased IgA has been shown in psoriasis [30]. Our results showed that non-treated plaque
psoriasis patients present increased plasma levels of Candida-specific IgA that correlate
with the IL-17 response to this fungus in vitro.
To evaluate Candida albicans exposure in psoriasis patients, fungus-specific immunoglob-
ulins in plasma were assessed. Significantly elevated levels of IgA and IgG against
Candida albicans were found in the plasma from plaque psoriasis patients, particularly
those with higher disease severity, compared to healthy controls. Current studies of
Candida albicans-specific immunoglobulins in psoriasis are controversial. One study re-
ported increased anti-whole cell antigen IgG but decreased anti-soluble antigen IgA and
IgM in psoriasis vulgaris versus healthy controls [21]. More recently, generally reduced
anti-CA immunoglobulins plasma levels in psoriasis vulgaris were shown, with no associa-
tion with disease severity or duration [6]. Importantly, 76% of their psoriasis cohort had
mild to moderate forms of the disease, which may explain the low levels of antibodies
detected compared to our results. To better characterize anti-C. albicans antibody response,
different subtypes of IgA and IgG were assessed. Both anti-CA IgA1 and IgA2 plasma lev-
els were increased in plaque psoriasis patients compared to guttate psoriasis and controls.
Human monomeric IgA subclasses are predominantly secreted by IgA-producing cells
in the bone marrow, but also in the spleen, synovial tissue and gingiva [31]. Specifically,
IgA1-secreting cells are present in the upper orogastric tract, whereas IgA2-secreting cells
predominate in the lower gastrointestinal tract [19]. B-cells activated in the gut-associated
lymphoid tissue (GALT) may be home to the marginal zone of the spleen [32]. Therefore,
the commensal or pathogenic-specific IgA produced by these GALT activated-plasma cells
may be secreted into the bloodstream. Despite being a commensal fungus, the presence
of higher levels of Candida albicans in both oral and gut samples from psoriasis patients is
widely demonstrated [33]. Altogether, our results identify both the oral and gut mucosa as
sites of encounter with C. albicans and IgA production. However, we cannot exclude the
possible existence of additional sources of CA-specific IgA in psoriasis, since its prevalence
in cutaneous tissues is not well-defined, and skin-homing IgA1- and IgA2-secreting cells
have also been described [19].
Memory CLA+ T cells participate in cutaneous immune responses due to their skin-
homing properties [34]. A preferential CLA+ T cell response to Candida albicans, dominated
by IL-17F, was found in psoriasis but also in control subjects. Although preferred C. albicans
induction of IL-9 on CLA+ T cells has already been shown in healthy donors [26], we ob-
served significantly increased CA-induced IL-9 response in psoriasis patients compared to
controls. We found differentiated T-cell responses to C. albicans stimuli between plaque and
guttate psoriasis, indicating increased cytokine responses in the latter. This finding is of spe-
cial interest since the IL-23/Th17 axis drives and maintains psoriasis pathogenesis [1] and
Candida albicans may fuel the IL-17/Th17 loop, thus perpetuating psoriasis. Of note, a recent
study observed that responses to commensal skin fungi, such as Candida albicans, enhance
psoriasiform Th17 inflammation in the imiquimod-induced psoriatic mice model [35].
Interestingly, we reported different humoral and cellular responses to Candida albicans
plaque and guttate psoriasis. Whereas C. albicans-specific antibody levels are increased
in the former, the T-cell response to C. albicans extract is higher in the latter. This may be
due to disparities in the course of each type of disease. While guttate psoriasis occurs in
a more acute way and generally has better prognosis, plaque psoriasis is usually more
severe, harder to control, and therefore, presents a more chronic duration. Plaque psoriasis
patients are more likely to receive immunosuppressive treatment intermittently and for
longer periods of time, which would cause microbiome dysbiosis, leading to increased
C. albicans colonization and an increased presence of specific IgA in plasma. Nevertheless,
because guttate psoriasis occurs more abruptly, skin and blood samples are usually taken
closely to the appearance of the flare, wherein pro-inflammatory CLA+ T cells in circulation
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are actively recruited to the cutaneous tissue. Conversely, in plaque psoriasis patients, the
recirculation of pro-inflammatory T-cells may diminish or rebalance over time, resulting
in a continuous flow of minor cells towards cutaneous lesions. This distinct presence of
active pro-inflammatory T-cells in circulation may explain the substantial response to CA
extract in cocultures from guttate psoriasis patients.
The link between Th17 and IgA has been extensively studied in animal models [36,37]
and humans. Although the molecular mechanisms underlying this effect are not fully
understood, Shibui A et al. suggested an indirect role for IL-17 in antibody production,
possibly by enhancing B-cell activators by other immune cells [38], whilst Ferreti E and
colleagues demonstrated how B-cell migration within germinal centers is modulated by
the IL-17A/IL-17RA axis [39]. A direct correlation between anti-CA IgA levels and IL-17
cytokines responses is found for both CLA+ and CLA− T only in cocultures from plaque
psoriasis patients. Recently, Wilson et al. reported the presence of antibody-secreting cells
(ASC) in healthy skin, secreting mainly IgM but also IgA and IgG, which are important
for maintaining tissue homeostasis [40]. The role of skin-associated B-cells in homeostasis
has also been recently reviewed [41], highlighting their interplay with other skin-resident
immune cells. We hypothesized that skin-associated B-cells may present Candida albicans
peptides to antigen-specific CLA+ T inducing its activation and fungus-specific antibody
secretion. Recently published data from our group demonstrated a similar correlation
between S. pyogenes-specific IgA and CLA+ T-cell IL-17 response in psoriasis [28]. However,
despite the direct correlation of the in vitro cytokine response to each antigen, no effect
of the association between psoriasis patients’ exposure to S. pyogenes and C. albicans on
IgA/G levels has been observed (data not shown). Nonetheless, IL-17 response by CLA−
T cells may contribute to C. albicans-specific IgA generation at extracutaneous sites, as
mentioned above.
Patients with high anti-CA IgA levels may carry pathophysiological peculiarities,
creating disease heterogeneity. Despite the fact that differentially expressed proteins were
not statistically significant after FDR correction, which remains a limitation of our study,
patients with high anti-CA IgA displayed generally increased levels of proteins involved
in antimicrobial humoral response, cell chemotaxis and inflammatory immune response.
Human RNASE3 is a cytotoxin with high anti-candida activity [42]. CHI3L1, which is
regulated by IL-17F/A [43,44], has also shown anti-candida properties [45]. Azurocidin,
secreted by neutrophils, acts against Candida albicans [46], and has been reported as a
biomarker for periodontal disease [47]. CCL18 mediates CLA+ memory T cells homing
towards skin [48]. Its expression is not only upregulated in lesions from atopic dermatitis
and psoriasis [49,50], but also gingival biopsies from periodontitis [51]. Increased CCL18,
CHI3L1 and AZU1 levels were detected in plasmas from plaque psoriasis, but we could
not confirm their association with anti-CA IgA levels, which remains a limitation of the
study. Our data support evidence linking the presence of C. albicans, psoriasis pathogenesis
and periodontal disease [52–54]. Nonetheless, longitudinal follow-up studies are required
to better establish a causal relationship.
We believe psoriasis patients’ increased cellular and humoral responses to C. albicans
appear as a consequence of increased exposure to this fungus. Th17 response is fundamen-
tal for fighting against Candida spp. infection [55], as it is key for psoriasis immunopatho-
genesis. Therefore, we hypothesize that our observation could be related to treatment
approaches for psoriasis. Effective therapies aim to reduce Th17 response in patients that
may facilitate fungal colonization and the subsequent promotion of IL-17 responses, thus fu-
eling psoriasis pathogenesis in a vicious circle. This hypothesis deserves careful analysis in
future clinical studies. On the other hand, a predisposing background to increased response
to C. albicans in psoriasis cannot be ruled out. Single nucleotide polymorphisms on IL-17
and IL-23 related genes, described as psoriasis genetic risk makers, could be associated to
altered responses to Candida spp., a matter that remains unexplored to our knowledge.
In summary, the presence of IgA against Candida albicans in plasma from patients
with plaque psoriasis without clinical signs of infection identifies subjects that have been
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exposed to this microbe, which preferentially activates skin-homing CLA+ T cells to secrete
IL17F and IL17A, two cytokines that are clinically demonstrated to be relevant in psoriasis
immunopathogenesis. We consider that Candida albicans exposure may affect psoriasis
evolution, and eventually response to therapies. Assessing anti-CA IgA levels may be
beneficial to better evaluate and stratify psoriasis patients.
4. Materials and Methods
4.1. Patients
All participants contributed voluntarily and provided written informed consent, and
human material collection has been approved by the corresponding Ethical Committees.
Psoriasis cohort 1 included non-treated patients with plaque or guttate lesions, without
any age or sex restriction. Exclusion criteria included any systemic treatment during the
4 weeks prior to the study or any topical treatment during the last 2 weeks. Psoriasis
cohort 2 comprised baseline plasma samples from the Clinical Trial NCT00778700, which
included plaque psoriasis involving 2 to 20% body surface area, and those aged from 18 to
75 years. Exclusion criteria included lesions solely involving intertriginous areas, the scalp
or the face, pustular psoriasis or erythroderma, systemic therapy, being currently on other
topical agents or UVB within 2 weeks of the first dose of study medication, having started
or discontinued therapy within 2 months of screening with agents that can exacerbate
psoriasis, or currently receiving systemic triazole antifungals.
4.2. ELISA
ELISAs were performed as previously described [28]. The antibodies are listed in
Supplementary Table S2. As the negative control of the experiment, CA-coated wells were
incubated with PBS-1% skimmed milk instead of plasma dilution. The titer of reactive anti-
CA antibody was taken as the OD405nm after background signal (OD570nm) and negative
control well signal subtraction, referred to as net OD 1/100. As a positive control of
the technique, the wells were coated with human IgA/G isotype controls (Invitrogen,
Carlsband, CA, USA), incubated with PBS as the primary antibody and a corresponding
secondary antibody before substrate addition.
4.3. Circulating Memory T-cell and Epidermal Cell Isolation
Peripheral blood mononuclear cells were isolated by Ficoll gradient (GE Healthcare,
Princeton, NJ, USA) and, after subsequent immunomagnetic separations (Miltenyi Biotech,
Bergisch Gladbach, Germany), memory CD45RA− CLA+ and CLA− T cells were purified
as previously described [56]. Punch skin biopsies (4–6 mm) were incubated overnight in
dispase (Corning, Corning, NY, USA) at 4 ◦C, then the epidermal sheet was peeled off
from the dermis. The epidermis was cut in pieces and incubated in trypsin (Biological
Industries, Kibbutz Beit Haemek, Israel) for 15 min at 37 ◦C. Epidermal tissue was then
mechanically disaggregated by gently pipetting and the cell suspension was transferred
to fresh culture media (RPMI, 10% FBS, 1% penicillin-streptomycin (SIGMA-Aldrich,
St. Louis, MO, USA)).
4.4. Co-Cultures
The ex vivo cocultures consisted of 5 × 104 CLA+/− T-cells plated together with
3 × 104 autologous epidermal cells at the same time (CLA+T/Epi or CLA−T/Epi, respec-
tively), seeded together simultaneously in 96-well flat-bottom plates (SIGMA-Aldrich,
St. Louis, MO, USA), in the culture media described above. Cocultures were left un-
treated or activated with CA extract (Stallergenes Greer, Lenoir, NC, USA) reconstituted
at 800 µg/mL in sterile water (SIGMA-Aldrich). CA extract was used at 20 µg/mL final
well concentration. After 5 days of culture, supernatants were collected and kept frozen at
−20 ◦C for later cytokine quantification.
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4.5. Cytokine Quantification
Multiplex fluorescent bead-based immunoassays were used to measure IL-17A and IFN-γ
(Diaclone SAS, Besançon, France) and IL-17F (BD Bioscience, Franklin Lakes, NJ, USA) con-
centration in collected culture supernatants. IL-9 concentration was quantified by using
pre-coated ELISA kits (Biolegend, San Diego, CA, USA).
4.6. Proteomic Study
Anti-CA IgA plasma levels were measured in 114 plasma samples collected at baseline
from psoriasis cohort 2. Patients were stratified into high (>3 OD, n = 61), intermediate
(1.5–2.9 OD, n = 26), and low (<1.5 OD, n = 27) IgA-Candida. Broad proteomic analysis
of plasma samples was conducted by OLINK Proteomics (n = 1012 proteins) (Watertown,
MA, USA) and compared between groups using a generalized linear model. For technical
information go to www.olink.com/downloads. Least-squared mean differences were used
to compare high vs. negative groups. Statistical analyses were conducted in Array Studio
version 10.1. Three of the differentially expressed proteins were selected for validation in a
different cohort of patients (cohort 1, n = 52) and healthy individuals (n = 16) via ELISA
(Fine test, Wuhan Fine Biotech Co., Ltd., Wuhan, China): RNASE3, AZU1, CHI3L1, CCL18,
FST and FSLG.
4.7. Statistical Analysis
GraphPad Prism software (Version 8, GraphPad Software Corporation, San Diego,
CA, USA) was used for statistical analysis and graphical representation. Data are generally
represented as the mean and 95% confidence interval (CI). Differences between two condi-
tions within the same group were analyzed by Wilcoxon test and represented by double
pointed lines. Differences between two groups were analyzed by the Mann–Whitney test
and represented by single pointed lines. Differences were considered significant at a p
value of less than 0.05 and represented by the following symbols: (ns): p > 0.05; (*): p < 0.05;
(**): p < 0.01 and (***): p < 0.001. The correlations were examined using Spearman’s rank
correlation, and the Spearman’s coefficient and p value are indicated for each test.
Supplementary Materials: The following are available online at https://www.mdpi.com/1422
-0067/22/4/1519/s1, Figure S1: quantitative measurement of anti-CA IgA plasma levels with a
commercial ELISA kit validate our results, Figure S2: Candida albicans cytokine response is not
induced in single cultures of epidermal or CLA+/− T cells, Figure S3: Correlations between CCL18,
Chi3L1 and AZU1 plasma levels with disease severity and onset in psoriasis, Table S1: Detailed
information on samples from psoriasis and healthy individuals, Table S2: List of antibodies and
concentrations used in the ELISA, Table S3: Differentially expressed proteins in psoriasis patients
with low versus high anti-CA IgA levels.
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